BIO INX® is a spin-off company from VUB and UGent that specializes in commercializing materials and bio-inks for 3D bioprinting or biofabrication. Leveraging decades of academic experience in polymers and biomaterials. BIO INX® was established as a result of a joint PhD research project between B-PHOT Brussels Photonics (VUB) and the Polymer Chemistry and Biomaterials Group (UGent).
BIO INX® offers a unique material portfolio with diverse material properties, enabling a wide range of applications. Their bio-inks are suitable for various tissue types, making them valuable in regenerative medicine, drug development, and cosmetics screening. Moreover, their bio-ink portfolio supports multiple printing technologies, allowing for resolutions ranging from hundreds of micrometers to hundreds of nanometers.
The BIO INX® team comprises experts from diverse fields such as chemistry and biomedical engineering, with a combined 20 years of experience in polymers, materials, 3D printing, and tissue engineering.
Since its creation, BIO INX has collaborated with renowned companies such as Carl ROTH, Readily3D, Rousselot, Puredyne to advance innovation in bioprinting.
Milestones
- 2022: closing first capital raise of €700,000
- 2023: new era in bioprinting with launch of bioinks from micro- to meso-scale
- 2024: 3DNatives Start-up of the Year
- 2024: launch of first biodegradable and biocompatible resin
- 2024: launch of groundbreaking gelatin-based DLP Resin
- 2025: groundbreaking study on advancing cancer research with 3D bioprinting
- 2025: fastest High-Resolution 3D (bio)printer ever reported uses BIO INX resins in its first trials
